trending Market Intelligence /marketintelligence/en/news-insights/trending/h3eG4wt6D-Ss27ldneX67g2 content esgSubNav
In This List

Venture capital firm Capital Point buys stake in Can-Fite BioPharma

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Venture capital firm Capital Point buys stake in Can-Fite BioPharma

Can-Fite BioPharma Ltd. said Capital Point Ltd. acquired more than 5% of the company's outstanding share capital.

The Israel-based venture capital firm has requested Can-Fite to initiate a shareholders meeting to replace the board.

Can-Fite Biopharma noted that it is conducting a review of Capital Point's letter to determine the appropriate actions.

Petah-Tikva, Israel-based Can-Fite Biopharma is developing products to treat autoimmune-inflammatory and cancer diseases.